comprehensive -WSS

comprehensive

author：focus 2025-09-27 19:18:54 Page View：68433

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO
Next article： Moonlake's readout produced a cash windfall. Risks remain

Wikipedia

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

The biotech scorecard for Q4: 16 stock

RyanPierse/GettyImagesHereisSTAT’sbiotechscorecard,ourregularledgerofstock-movingbiotechevents,forth

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

Study points to new risk in gene therapy death of Terry Horgan

TerryHorganinhisfamily'sMontourFalls,N.Y.,home,inanundatedphoto.KateCollins/TheJournalviaAPLastOctob

comprehensive

explore

Wikipedia

Study points to new risk in gene therapy death of Terry Horgan